GSK infuses $120M into next-gen manufacturing facilities at Upper Merion, PA
In the latest move to bring its manufacturing capabilities up to speed with the latest technological advances, GlaxoSmithKline has dedicated $120 million to an expansion at its longtime site in Upper Merion, Pennsylvania.
The upgrade is meant to render the facility more flexible than traditional manufacturing operations, GSK said. You can expect to see single-use and disposable components, allowing for a quick transition between the production of one medicine to another; streamlined quality and commercial testing processes; as well as a new analytical lab.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.